{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T10:46:29Z","timestamp":1794480389787,"version":"4.9.1"},"reference-count":48,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,26]],"date-time":"2025-09-26T00:00:00Z","timestamp":1758844800000},"content-version":"am","delay-in-days":268,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000053","name":"National Eye Institute","doi-asserted-by":"publisher","award":["P30EY022589"],"award-info":[{"award-number":["P30EY022589"]}],"id":[{"id":"10.13039\/100000053","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000053","name":"National Eye Institute","doi-asserted-by":"publisher","award":["DP5OD029610"],"award-info":[{"award-number":["DP5OD029610"]}],"id":[{"id":"10.13039\/100000053","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000053","name":"National Eye Institute","doi-asserted-by":"publisher","award":["R01EY034115"],"award-info":[{"award-number":["R01EY034115"]}],"id":[{"id":"10.13039\/100000053","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000053","name":"National Eye Institute","doi-asserted-by":"publisher","award":["P30EY001583"],"award-info":[{"award-number":["P30EY001583"]}],"id":[{"id":"10.13039\/100000053","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000053","name":"National Eye Institute","doi-asserted-by":"publisher","award":["OT2OD032644"],"award-info":[{"award-number":["OT2OD032644"]}],"id":[{"id":"10.13039\/100000053","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000053","name":"National Eye Institute","doi-asserted-by":"publisher","award":["US20220193201A1"],"award-info":[{"award-number":["US20220193201A1"]}],"id":[{"id":"10.13039\/100000053","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001818","name":"Research to Prevent Blindness","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001818","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007911","name":"University of California, San Diego","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007911","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002924","name":"Glaucoma Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002924","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["ajo.com","clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Ophthalmology"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1016\/j.ajo.2024.08.030","type":"journal-article","created":{"date-parts":[[2024,9,3]],"date-time":"2024-09-03T19:05:47Z","timestamp":1725390347000},"page":"255-265","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"special_numbering":"C","title":["Association Between Glucagon-Like Peptide-1 Receptor Agonists Exposure and Intraocular Pressure Change"],"prefix":"10.1016","volume":"269","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9541-1915","authenticated-orcid":false,"given":"Shahin","family":"Hallaj","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Halfpenny","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0354-0569","authenticated-orcid":false,"given":"Benton G.","family":"Chuter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9553-3202","authenticated-orcid":false,"given":"Robert N.","family":"Weinreb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5271-7690","authenticated-orcid":false,"given":"Sally L.","family":"Baxter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5338-0401","authenticated-orcid":false,"given":"Qi N.","family":"Cui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"12","key":"10.1016\/j.ajo.2024.08.030_bib0001","first-page":"1296","article-title":"Antibody and protein profiles in glaucoma: screening of biomarkers and identification of signaling pathways","volume":"10","author":"Auler","year":"2021","journal-title":"Biology (Basel)"},{"issue":"11","key":"10.1016\/j.ajo.2024.08.030_bib0002","first-page":"1181","article-title":"Cell-based neuroprotection of retinal ganglion cells in animal models of optic neuropathies","volume":"10","author":"Hu","year":"2021","journal-title":"Biology (Basel)"},{"issue":"1","key":"10.1016\/j.ajo.2024.08.030_bib0003","doi-asserted-by":"crossref","DOI":"10.1136\/bmjophth-2016-000032","article-title":"Retinal vasculature in glaucoma: a review","volume":"1","author":"Chan","year":"2017","journal-title":"BMJ Open Ophth"},{"issue":"6","key":"10.1016\/j.ajo.2024.08.030_bib0004","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.3390\/cells10061372","article-title":"Multifactorial pathogenic processes of retinal ganglion cell degeneration in glaucoma towards multi-target strategies for broader treatment effects","volume":"10","author":"Tezel","year":"2021","journal-title":"Cells"},{"issue":"2","key":"10.1016\/j.ajo.2024.08.030_bib0005","doi-asserted-by":"crossref","first-page":"238","DOI":"10.3390\/antiox10020238","article-title":"Oxidative stress and the role of NADPH oxidase in glaucoma","volume":"10","author":"Fan Gaskin","year":"2021","journal-title":"Antioxidants (Basel)"},{"key":"10.1016\/j.ajo.2024.08.030_bib0006","first-page":"3","article-title":"Evidence of oxidative stress damage in glaucoma","volume":"6","author":"Ferreira","year":"2011","journal-title":"The Mystery of Glaucoma"},{"issue":"2","key":"10.1016\/j.ajo.2024.08.030_bib0007","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.mrrev.2005.11.001","article-title":"The role of oxidative stress in glaucoma","volume":"612","author":"Izzotti","year":"2006","journal-title":"Mutat Res"},{"issue":"1","key":"10.1016\/j.ajo.2024.08.030_bib0008","article-title":"The trabecular meshwork: a basic review of form and function","volume":"2","author":"Abu-Hassan","year":"2014","journal-title":"J Ocul Biol"},{"issue":"2","key":"10.1016\/j.ajo.2024.08.030_bib0009","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1007\/s40135-019-00203-2","article-title":"Trabecular meshwork regeneration\u2014a potential treatment for glaucoma","volume":"7","author":"Castro","year":"2019","journal-title":"Curr Ophthalmol Rep"},{"key":"10.1016\/j.ajo.2024.08.030_bib0010","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2022.1083130","article-title":"Cell senescence alters responses of porcine trabecular meshwork cells to shear stress","volume":"10","author":"Du","year":"2022","journal-title":"Front Cell Dev Biol"},{"issue":"14","key":"10.1016\/j.ajo.2024.08.030_bib0011","doi-asserted-by":"crossref","first-page":"ORSF60","DOI":"10.1167\/iovs.13-12716","article-title":"Glaucoma: a disease of early cellular senescence","volume":"54","author":"Caprioli","year":"2013","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"9","key":"10.1016\/j.ajo.2024.08.030_bib0012","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.3390\/biom11091258","article-title":"Cell-based therapies for trabecular meshwork regeneration to treat glaucoma","volume":"11","author":"Mallick","year":"2021","journal-title":"Biomolecules"},{"issue":"7","key":"10.1016\/j.ajo.2024.08.030_bib0013","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1038\/s41574-018-0016-2","article-title":"Glucagon-like peptide 1 in health and disease","volume":"14","author":"Andersen","year":"2018","journal-title":"Nat Rev Endocrinol"},{"key":"10.1016\/j.ajo.2024.08.030_bib0014","doi-asserted-by":"crossref","DOI":"10.1177\/2042018821997320","article-title":"GLP-1 receptor agonists: an updated review of head-to-head clinical studies","volume":"12","author":"Trujillo","year":"2021","journal-title":"Ther Adv Endocrinol Metab"},{"issue":"6","key":"10.1016\/j.ajo.2024.08.030_bib0015","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0126769","article-title":"The effect of glucagon-like peptide 1 receptor agonists on weight loss in type 2 diabetes: a systematic review and mixed treatment comparison meta-analysis","volume":"10","author":"Potts","year":"2015","journal-title":"PLoS One"},{"issue":"17","key":"10.1016\/j.ajo.2024.08.030_bib0016","doi-asserted-by":"crossref","first-page":"9583","DOI":"10.3390\/ijms23179583","article-title":"Anti-inflammatory effects of GLP-1 receptor activation in the brain in neurodegenerative diseases","volume":"23","author":"Diz-Chaves","year":"2022","journal-title":"Int J Mol Sci"},{"issue":"5","key":"10.1016\/j.ajo.2024.08.030_bib0017","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1016\/j.drudis.2016.01.013","article-title":"The glucagon-like peptide 1 (GLP) receptor as a therapeutic target in Parkinson's disease: mechanisms of action","volume":"21","author":"Athauda","year":"2016","journal-title":"Drug Discov Today"},{"key":"10.1016\/j.ajo.2024.08.030_bib0018","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/1742-2094-5-19","article-title":"Glucagon-like peptide 1 receptor stimulation reverses key deficits in distinct rodent models of Parkinson's disease","volume":"5","author":"Harkavyi","year":"2008","journal-title":"J Neuroinflammation"},{"issue":"5","key":"10.1016\/j.ajo.2024.08.030_bib0019","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2020.108271","article-title":"GLP-1 receptor agonist NLY01 reduces retinal inflammation and neuron death secondary to ocular hypertension","volume":"33","author":"Sterling","year":"2020","journal-title":"Cell Rep"},{"issue":"4","key":"10.1016\/j.ajo.2024.08.030_bib0020","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1111\/bph.15683","article-title":"The role of glia in the physiology and pharmacology of glucagon-like peptide-1: implications for obesity, diabetes, neurodegeneration and glaucoma","volume":"179","author":"Cui","year":"2022","journal-title":"Br J Pharmacol"},{"issue":"12","key":"10.1016\/j.ajo.2024.08.030_bib0021","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2020.107776","article-title":"Neurotoxic reactive astrocytes drive neuronal death after retinal injury","volume":"31","author":"Guttenplan","year":"2020","journal-title":"Cell Rep"},{"issue":"4","key":"10.1016\/j.ajo.2024.08.030_bib0022","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1073\/pnas.0806720106","article-title":"GLP-1 receptor stimulation preserves primary cortical and dopaminergic neurons in cellular and rodent models of stroke and Parkinsonism","volume":"106","author":"Li","year":"2009","journal-title":"Proc Natl Acad Sci USA"},{"issue":"2","key":"10.1016\/j.ajo.2024.08.030_bib0023","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1002\/jnr.21483","article-title":"Peptide hormone exendin-4 stimulates subventricular zone neurogenesis in the adult rodent brain and induces recovery in an animal model of Parkinson's disease","volume":"86","author":"Bertilsson","year":"2008","journal-title":"J Neurosci Res"},{"issue":"4","key":"10.1016\/j.ajo.2024.08.030_bib0024","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1016\/j.neuroscience.2010.08.028","article-title":"Val8-glucagon-like peptide-1 protects against A\u03b21-40-induced impairment of hippocampal late-phase long-term potentiation and spatial learning in rats","volume":"170","author":"Wang","year":"2010","journal-title":"Neuroscience"},{"issue":"2","key":"10.1016\/j.ajo.2024.08.030_bib0025","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1016\/j.neurobiolaging.2012.04.009","article-title":"Liraglutide protects against amyloid-\u03b2 protein-induced impairment of spatial learning and memory in rats","volume":"34","author":"Han","year":"2013","journal-title":"Neurobiol Aging"},{"issue":"4","key":"10.1016\/j.ajo.2024.08.030_bib0026","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.3233\/JAD-2010-1314","article-title":"GLP-1 receptor stimulation reduces amyloid-beta peptide accumulation and cytotoxicity in cellular and animal models of Alzheimer's disease","volume":"19","author":"Li","year":"2010","journal-title":"J Alzheimers Dis"},{"issue":"10","key":"10.1016\/j.ajo.2024.08.030_bib0027","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1111\/j.1463-1326.2010.01259.x","article-title":"Four weeks administration of Liraglutide improves memory and learning as well as glycaemic control in mice with high fat dietary-induced obesity and insulin resistance","volume":"12","author":"Porter","year":"2010","journal-title":"Diabetes Obes Metab"},{"issue":"6","key":"10.1016\/j.ajo.2024.08.030_bib0028","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1080\/02699052.2019.1587000","article-title":"GLP-1\u2019s role in neuroprotection: a systematic review","volume":"33","author":"Erbil","year":"2019","journal-title":"Brain Inj"},{"issue":"2","key":"10.1016\/j.ajo.2024.08.030_bib0029","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1136\/bjophthalmol-2021-319232","article-title":"Glucagon-like peptide 1 receptor agonist use is associated with reduced risk for glaucoma","volume":"107","author":"Sterling","year":"2023","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.ajo.2024.08.030_bib0030","doi-asserted-by":"crossref","DOI":"10.1016\/j.ophtha.2024.03.004","article-title":"Association between glucagon-like peptide-1 receptor agonists and the risk of glaucoma in individuals with type 2 diabetes","author":"Niazi","year":"2024","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ajo.2024.08.030_bib0031","doi-asserted-by":"crossref","DOI":"10.3389\/fncel.2023.1156829","article-title":"Topical and systemic GLP-1R agonist administration both rescue retinal ganglion cells in hypertensive glaucoma","volume":"17","author":"Lawrence","year":"2023","journal-title":"Front Cell Neurosci"},{"key":"10.1016\/j.ajo.2024.08.030_bib0032","first-page":"467","article-title":"Conversion of national health insurance service-national sample cohort (NHIS-NSC) database into observational Medical Outcomes Partnership-Common Data Model (OMOP-CDM)","volume":"245","author":"You","year":"2017","journal-title":"Stud Health Technol Inform"},{"key":"10.1016\/j.ajo.2024.08.030_bib0033","unstructured":"University of California Health. Center for data-driven insights and innovation (CDI2). 2024. Accessed March 15, 2024. https:\/\/www.ucop.edu\/uc-health\/departments\/center-for-data-driven-insights-and-innovations-cdi2.html."},{"issue":"10","key":"10.1016\/j.ajo.2024.08.030_bib0034","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.1007\/s00417-019-04354-7","article-title":"Acute and chronic optic nerve head biomechanics and intraocular pressure changes in patients receiving multiple intravitreal injections of anti-VEGF","volume":"257","author":"G\u00f3mez-Mariscal","year":"2019","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"4","key":"10.1016\/j.ajo.2024.08.030_bib0035","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1001\/jamaophthalmol.2017.0059","article-title":"Association of repeated intravitreous bevacizumab injections with risk for glaucoma surgery","volume":"135","author":"Eadie","year":"2017","journal-title":"JAMA Ophthalmol"},{"issue":"3","key":"10.1016\/j.ajo.2024.08.030_bib0036","first-page":"368","article-title":"Changes in intraocular pressure with use of periocular triamcinolone cream","volume":"17","author":"H Kim D","year":"2022","journal-title":"J Ophthalmic Vis Res"},{"issue":"1","key":"10.1016\/j.ajo.2024.08.030_bib0037","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1186\/s12886-019-1187-x","article-title":"The effect of multiple vitrectomies and its indications on intraocular pressure","volume":"19","author":"Kovacic","year":"2019","journal-title":"BMC Ophthalmol"},{"issue":"13","key":"10.1016\/j.ajo.2024.08.030_bib0038","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.3390\/cells11132023","article-title":"GLP-1 receptor agonists in neurodegeneration: neurovascular unit in the spotlight","volume":"11","author":"Monti","year":"2022","journal-title":"Cells"},{"issue":"3","key":"10.1016\/j.ajo.2024.08.030_bib0039","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1007\/s13311-021-01088-5","article-title":"Therapeutic potential of a novel glucagon-like peptide-1 receptor agonist, NLY01, in experimental autoimmune encephalomyelitis","volume":"18","author":"Gharagozloo","year":"2021","journal-title":"Neurotherapeutics"},{"issue":"1","key":"10.1016\/j.ajo.2024.08.030_bib0040","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabet.2022.101318","article-title":"Association between sodium glucose co-transporter 2 inhibitors and incident glaucoma in patients with type 2 diabetes: a multi-institutional cohort study in Taiwan","volume":"48","author":"Shao","year":"2022","journal-title":"Diabetes Metab"},{"issue":"1","key":"10.1016\/j.ajo.2024.08.030_bib0041","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.ophtha.2015.09.027","article-title":"Trabeculectomy can improve long-term visual function in glaucoma","volume":"123","author":"Caprioli","year":"2016","journal-title":"Ophthalmology"},{"issue":"4","key":"10.1016\/j.ajo.2024.08.030_bib0042","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1016\/j.ophtha.2008.12.036","article-title":"Variability of intraocular pressure measurements in observation participants in the ocular hypertension treatment study","volume":"116","author":"Bhorade","year":"2009","journal-title":"Ophthalmology"},{"issue":"5","key":"10.1016\/j.ajo.2024.08.030_bib0043","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.1093\/brain\/awad003","article-title":"The effect of GLP-1RA exenatide on idiopathic intracranial hypertension: a randomized clinical trial","volume":"146","author":"Mitchell","year":"2023","journal-title":"Brain"},{"issue":"404","key":"10.1016\/j.ajo.2024.08.030_bib0044","doi-asserted-by":"crossref","first-page":"eaan0972","DOI":"10.1126\/scitranslmed.aan0972","article-title":"A glucagon-like peptide-1 receptor agonist reduces intracranial pressure in a rat model of hydrocephalus","volume":"9","author":"Botfield","year":"2017","journal-title":"Sci Transl Med"},{"issue":"1","key":"10.1016\/j.ajo.2024.08.030_bib0045","doi-asserted-by":"crossref","DOI":"10.1136\/bmjophth-2023-001355","article-title":"Lolok GB Role of excessive weight in intraocular pressure: a systematic review and meta-analysis","volume":"8","author":"Waspodo","year":"2023","journal-title":"BMJ Open Ophth"},{"issue":"8","key":"10.1016\/j.ajo.2024.08.030_bib0046","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1016\/j.ophtha.2017.12.001","article-title":"The 2016 American Academy of Ophthalmology IRIS\u00ae Registry (Intelligent Research in Sight) database: characteristics and methods","volume":"125","author":"Chiang","year":"2018","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ajo.2024.08.030_bib0047","unstructured":"All of us research program | National Institutes of Health (NIH). Accessed March 25, 2024. https:\/\/allofus.nih.gov\/"},{"key":"10.1016\/j.ajo.2024.08.030_bib0048","unstructured":"National Institutes of Health. All of us research program. All of us research hub. 2024. Accessed March 15, 2024. https:\/\/researchallofus.org\/."}],"container-title":["American Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002939424003921?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002939424003921?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,3]],"date-time":"2025-02-03T17:21:22Z","timestamp":1738603282000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002939424003921"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":48,"alternative-id":["S0002939424003921"],"URL":"https:\/\/doi.org\/10.1016\/j.ajo.2024.08.030","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2024.05.06.24306943","asserted-by":"object"}]},"ISSN":["0002-9394"],"issn-type":[{"value":"0002-9394","type":"print"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Association Between Glucagon-Like Peptide-1 Receptor Agonists Exposure and Intraocular Pressure Change","name":"articletitle","label":"Article Title"},{"value":"American Journal of Ophthalmology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ajo.2024.08.030","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}